Ethyl Vanillin Activates TRPA1

The nonselective cation channel transient receptor potential ankryn subtype family 1 (TRPA1) is expressed in neurons of dorsal root ganglia and trigeminal ganglia and also in vagal afferent neurons that innervate the lungs and gastrointestinal tract. Many TRPA1 agonists are reactive electrophilic co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2017-09, Vol.362 (3), p.368-377
Hauptverfasser: Wu, Shaw-wen, Fowler, Daniel K., Shaffer, Forrest J., Lindberg, Jonathon E.M., Peters, James H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 377
container_issue 3
container_start_page 368
container_title The Journal of pharmacology and experimental therapeutics
container_volume 362
creator Wu, Shaw-wen
Fowler, Daniel K.
Shaffer, Forrest J.
Lindberg, Jonathon E.M.
Peters, James H.
description The nonselective cation channel transient receptor potential ankryn subtype family 1 (TRPA1) is expressed in neurons of dorsal root ganglia and trigeminal ganglia and also in vagal afferent neurons that innervate the lungs and gastrointestinal tract. Many TRPA1 agonists are reactive electrophilic compounds that form covalent adducts with TRPA1. Allyl isothiocyanate (AITC), the common agonist used to identify TRPA1, contains an electrophilic group that covalently binds with cysteine residues of TRPA1 and confers a structural change on the channel. There is scientific motivation to identify additional compounds that can activate TRPA1 with different mechanisms of channel gating. We provide evidence that ethyl vanillin (EVA) is a TRPA1 agonist. Using fluorescent calcium imaging and whole-cell patch-clamp electrophysiology on dissociated rat vagal afferent neurons and TRPA1-transfected COS-7 cells, we discovered that EVA activates cells also activated by AITC. Both agonists display similar current profiles and conductances. Pretreatment with A967079, a selective TRPA1 antagonist, blocks the EVA response as well as the AITC response. Furthermore, EVA does not activate vagal afferent neurons from TRPA1 knockout mice, showing selectivity for TRPA1 in this tissue. Interestingly, EVA appears to be pharmacologically different from AITC as a TRPA1 agonist. When AITC is applied before EVA, the EVA response is occluded. However, they both require intracellular oxidation to activate TRPA1. These findings suggest that EVA activates TRPA1 but via a distinct mechanism that may provide greater ease for study in native systems compared with AITC and may shed light on differential modes of TRPA1 gating by ligand types.
doi_str_mv 10.1124/jpet.116.239384
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5539581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524196334</els_id><sourcerecordid>1910792951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-bb4eec3a2b8638c56d0c43cff59b02ddca0b0284050f755be6acf545dbc6d6133</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlbP3kqPXrbNd3cvQin1AwqKVK8hm8zalO1uTdJC_71bthY9eJqBeead4UHoluAhIZSPVhuITSeHlGUs5WeoSwQlCSaYnaMuxpQmTEjRQVchrDAmnEt2iTo0lRQTiruoP4vLfTn40JUrS1cNJia6nY4QBou31wm5RheFLgPcHGsPvT_MFtOnZP7y-DydzBPDOYtJnnMAwzTNU8lSI6TFhjNTFCLLMbXWaNzUlGOBi7EQOUhtCsGFzY20kjDWQ_dt7mabr8EaqKLXpdp4t9Z-r2rt1N9J5Zbqs94pIVgmUtIE3B0DfP21hRDV2gUDZakrqLdBkYzgcUYzcUBHLWp8HYKH4nSGYHWwqg5Wm06q1mqz0f_93Yn_0dgAWQtA42jnwKtgHFQGrPNgorK1-zf8Gyn9hlk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1910792951</pqid></control><display><type>article</type><title>Ethyl Vanillin Activates TRPA1</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Wu, Shaw-wen ; Fowler, Daniel K. ; Shaffer, Forrest J. ; Lindberg, Jonathon E.M. ; Peters, James H.</creator><creatorcontrib>Wu, Shaw-wen ; Fowler, Daniel K. ; Shaffer, Forrest J. ; Lindberg, Jonathon E.M. ; Peters, James H.</creatorcontrib><description>The nonselective cation channel transient receptor potential ankryn subtype family 1 (TRPA1) is expressed in neurons of dorsal root ganglia and trigeminal ganglia and also in vagal afferent neurons that innervate the lungs and gastrointestinal tract. Many TRPA1 agonists are reactive electrophilic compounds that form covalent adducts with TRPA1. Allyl isothiocyanate (AITC), the common agonist used to identify TRPA1, contains an electrophilic group that covalently binds with cysteine residues of TRPA1 and confers a structural change on the channel. There is scientific motivation to identify additional compounds that can activate TRPA1 with different mechanisms of channel gating. We provide evidence that ethyl vanillin (EVA) is a TRPA1 agonist. Using fluorescent calcium imaging and whole-cell patch-clamp electrophysiology on dissociated rat vagal afferent neurons and TRPA1-transfected COS-7 cells, we discovered that EVA activates cells also activated by AITC. Both agonists display similar current profiles and conductances. Pretreatment with A967079, a selective TRPA1 antagonist, blocks the EVA response as well as the AITC response. Furthermore, EVA does not activate vagal afferent neurons from TRPA1 knockout mice, showing selectivity for TRPA1 in this tissue. Interestingly, EVA appears to be pharmacologically different from AITC as a TRPA1 agonist. When AITC is applied before EVA, the EVA response is occluded. However, they both require intracellular oxidation to activate TRPA1. These findings suggest that EVA activates TRPA1 but via a distinct mechanism that may provide greater ease for study in native systems compared with AITC and may shed light on differential modes of TRPA1 gating by ligand types.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.116.239384</identifier><identifier>PMID: 28620120</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Benzaldehydes - pharmacology ; Cercopithecus aethiops ; COS Cells ; HEK293 Cells ; Humans ; Isothiocyanates - pharmacology ; Male ; Mice ; Neurons, Afferent - drug effects ; Neurons, Afferent - metabolism ; Neuropharmacology ; Nodose Ganglion - cytology ; Nodose Ganglion - drug effects ; Oximes - pharmacology ; Patch-Clamp Techniques ; Rats ; Rats, Sprague-Dawley ; TRPA1 Cation Channel ; TRPC Cation Channels - agonists ; TRPC Cation Channels - antagonists &amp; inhibitors ; TRPC Cation Channels - genetics</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2017-09, Vol.362 (3), p.368-377</ispartof><rights>2017 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.</rights><rights>Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-bb4eec3a2b8638c56d0c43cff59b02ddca0b0284050f755be6acf545dbc6d6133</citedby><cites>FETCH-LOGICAL-c443t-bb4eec3a2b8638c56d0c43cff59b02ddca0b0284050f755be6acf545dbc6d6133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28620120$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Shaw-wen</creatorcontrib><creatorcontrib>Fowler, Daniel K.</creatorcontrib><creatorcontrib>Shaffer, Forrest J.</creatorcontrib><creatorcontrib>Lindberg, Jonathon E.M.</creatorcontrib><creatorcontrib>Peters, James H.</creatorcontrib><title>Ethyl Vanillin Activates TRPA1</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>The nonselective cation channel transient receptor potential ankryn subtype family 1 (TRPA1) is expressed in neurons of dorsal root ganglia and trigeminal ganglia and also in vagal afferent neurons that innervate the lungs and gastrointestinal tract. Many TRPA1 agonists are reactive electrophilic compounds that form covalent adducts with TRPA1. Allyl isothiocyanate (AITC), the common agonist used to identify TRPA1, contains an electrophilic group that covalently binds with cysteine residues of TRPA1 and confers a structural change on the channel. There is scientific motivation to identify additional compounds that can activate TRPA1 with different mechanisms of channel gating. We provide evidence that ethyl vanillin (EVA) is a TRPA1 agonist. Using fluorescent calcium imaging and whole-cell patch-clamp electrophysiology on dissociated rat vagal afferent neurons and TRPA1-transfected COS-7 cells, we discovered that EVA activates cells also activated by AITC. Both agonists display similar current profiles and conductances. Pretreatment with A967079, a selective TRPA1 antagonist, blocks the EVA response as well as the AITC response. Furthermore, EVA does not activate vagal afferent neurons from TRPA1 knockout mice, showing selectivity for TRPA1 in this tissue. Interestingly, EVA appears to be pharmacologically different from AITC as a TRPA1 agonist. When AITC is applied before EVA, the EVA response is occluded. However, they both require intracellular oxidation to activate TRPA1. These findings suggest that EVA activates TRPA1 but via a distinct mechanism that may provide greater ease for study in native systems compared with AITC and may shed light on differential modes of TRPA1 gating by ligand types.</description><subject>Animals</subject><subject>Benzaldehydes - pharmacology</subject><subject>Cercopithecus aethiops</subject><subject>COS Cells</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Isothiocyanates - pharmacology</subject><subject>Male</subject><subject>Mice</subject><subject>Neurons, Afferent - drug effects</subject><subject>Neurons, Afferent - metabolism</subject><subject>Neuropharmacology</subject><subject>Nodose Ganglion - cytology</subject><subject>Nodose Ganglion - drug effects</subject><subject>Oximes - pharmacology</subject><subject>Patch-Clamp Techniques</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>TRPA1 Cation Channel</subject><subject>TRPC Cation Channels - agonists</subject><subject>TRPC Cation Channels - antagonists &amp; inhibitors</subject><subject>TRPC Cation Channels - genetics</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMotlbP3kqPXrbNd3cvQin1AwqKVK8hm8zalO1uTdJC_71bthY9eJqBeead4UHoluAhIZSPVhuITSeHlGUs5WeoSwQlCSaYnaMuxpQmTEjRQVchrDAmnEt2iTo0lRQTiruoP4vLfTn40JUrS1cNJia6nY4QBou31wm5RheFLgPcHGsPvT_MFtOnZP7y-DydzBPDOYtJnnMAwzTNU8lSI6TFhjNTFCLLMbXWaNzUlGOBi7EQOUhtCsGFzY20kjDWQ_dt7mabr8EaqKLXpdp4t9Z-r2rt1N9J5Zbqs94pIVgmUtIE3B0DfP21hRDV2gUDZakrqLdBkYzgcUYzcUBHLWp8HYKH4nSGYHWwqg5Wm06q1mqz0f_93Yn_0dgAWQtA42jnwKtgHFQGrPNgorK1-zf8Gyn9hlk</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Wu, Shaw-wen</creator><creator>Fowler, Daniel K.</creator><creator>Shaffer, Forrest J.</creator><creator>Lindberg, Jonathon E.M.</creator><creator>Peters, James H.</creator><general>Elsevier Inc</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201709</creationdate><title>Ethyl Vanillin Activates TRPA1</title><author>Wu, Shaw-wen ; Fowler, Daniel K. ; Shaffer, Forrest J. ; Lindberg, Jonathon E.M. ; Peters, James H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-bb4eec3a2b8638c56d0c43cff59b02ddca0b0284050f755be6acf545dbc6d6133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Benzaldehydes - pharmacology</topic><topic>Cercopithecus aethiops</topic><topic>COS Cells</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Isothiocyanates - pharmacology</topic><topic>Male</topic><topic>Mice</topic><topic>Neurons, Afferent - drug effects</topic><topic>Neurons, Afferent - metabolism</topic><topic>Neuropharmacology</topic><topic>Nodose Ganglion - cytology</topic><topic>Nodose Ganglion - drug effects</topic><topic>Oximes - pharmacology</topic><topic>Patch-Clamp Techniques</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>TRPA1 Cation Channel</topic><topic>TRPC Cation Channels - agonists</topic><topic>TRPC Cation Channels - antagonists &amp; inhibitors</topic><topic>TRPC Cation Channels - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Shaw-wen</creatorcontrib><creatorcontrib>Fowler, Daniel K.</creatorcontrib><creatorcontrib>Shaffer, Forrest J.</creatorcontrib><creatorcontrib>Lindberg, Jonathon E.M.</creatorcontrib><creatorcontrib>Peters, James H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Shaw-wen</au><au>Fowler, Daniel K.</au><au>Shaffer, Forrest J.</au><au>Lindberg, Jonathon E.M.</au><au>Peters, James H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ethyl Vanillin Activates TRPA1</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2017-09</date><risdate>2017</risdate><volume>362</volume><issue>3</issue><spage>368</spage><epage>377</epage><pages>368-377</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>The nonselective cation channel transient receptor potential ankryn subtype family 1 (TRPA1) is expressed in neurons of dorsal root ganglia and trigeminal ganglia and also in vagal afferent neurons that innervate the lungs and gastrointestinal tract. Many TRPA1 agonists are reactive electrophilic compounds that form covalent adducts with TRPA1. Allyl isothiocyanate (AITC), the common agonist used to identify TRPA1, contains an electrophilic group that covalently binds with cysteine residues of TRPA1 and confers a structural change on the channel. There is scientific motivation to identify additional compounds that can activate TRPA1 with different mechanisms of channel gating. We provide evidence that ethyl vanillin (EVA) is a TRPA1 agonist. Using fluorescent calcium imaging and whole-cell patch-clamp electrophysiology on dissociated rat vagal afferent neurons and TRPA1-transfected COS-7 cells, we discovered that EVA activates cells also activated by AITC. Both agonists display similar current profiles and conductances. Pretreatment with A967079, a selective TRPA1 antagonist, blocks the EVA response as well as the AITC response. Furthermore, EVA does not activate vagal afferent neurons from TRPA1 knockout mice, showing selectivity for TRPA1 in this tissue. Interestingly, EVA appears to be pharmacologically different from AITC as a TRPA1 agonist. When AITC is applied before EVA, the EVA response is occluded. However, they both require intracellular oxidation to activate TRPA1. These findings suggest that EVA activates TRPA1 but via a distinct mechanism that may provide greater ease for study in native systems compared with AITC and may shed light on differential modes of TRPA1 gating by ligand types.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28620120</pmid><doi>10.1124/jpet.116.239384</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2017-09, Vol.362 (3), p.368-377
issn 0022-3565
1521-0103
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5539581
source MEDLINE; Alma/SFX Local Collection
subjects Animals
Benzaldehydes - pharmacology
Cercopithecus aethiops
COS Cells
HEK293 Cells
Humans
Isothiocyanates - pharmacology
Male
Mice
Neurons, Afferent - drug effects
Neurons, Afferent - metabolism
Neuropharmacology
Nodose Ganglion - cytology
Nodose Ganglion - drug effects
Oximes - pharmacology
Patch-Clamp Techniques
Rats
Rats, Sprague-Dawley
TRPA1 Cation Channel
TRPC Cation Channels - agonists
TRPC Cation Channels - antagonists & inhibitors
TRPC Cation Channels - genetics
title Ethyl Vanillin Activates TRPA1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T06%3A45%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ethyl%20Vanillin%20Activates%20TRPA1&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Wu,%20Shaw-wen&rft.date=2017-09&rft.volume=362&rft.issue=3&rft.spage=368&rft.epage=377&rft.pages=368-377&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.116.239384&rft_dat=%3Cproquest_pubme%3E1910792951%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1910792951&rft_id=info:pmid/28620120&rft_els_id=S0022356524196334&rfr_iscdi=true